Baidu
map
J AMB INTEL HUM COMP 润色咨询

Journal of Ambient Intelligence and Humanized Computing

出版年份：暂无数据 年文章数：1270 投稿命中率： 开通期刊会员，数据随心看

出版周期：Bimonthly 自引率：13.3% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1106563, encodeId=01f511065632a, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106564, encodeId=6907110656465, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859636, encodeId=08ad859636d5, content=14 october 2019 / accepted: 6 april 2020 / online first： 19 april 2020<br> 2019.10.14 投稿<br> 2020.1.16 返修：三个审稿人：意见中肯<br> 2020.2.2 修回<br> 2020.3.26 再次返修：这次是小修，主要修改参考文献格式<br> 2020.3.29 修回<br> 2020.4.6 接受<br> 2020.4.19 线上发表 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Mon Apr 20 12:50:53 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=853997, encodeId=b08c85399ea9, content=去年十一月投稿，三个月后大修，三个审稿人，给的意见大部分都很中肯，修改了七八天提交后三个月小修，修改两三天后提交后一个月后再次小修，修改提交后一个月后接收，整个过程很长。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11cc5414110, createdName=ms8592312893450551, createdTime=Sat Sep 28 08:19:05 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=845478, encodeId=8cb68454e863, content=年前投稿，5月收到大修意见，专家意见提得很专业也很具体，6月修改提交，今天7月中旬收到录用通知。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae65413999, createdName=ms4600315023772712, createdTime=Thu Jul 19 19:21:34 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=843984, encodeId=924d843984ce, content=审稿速度较慢，每次都是顶格给审稿意见。<br> 专家给的意见还是很靠谱，经历了两轮小修才正式录用，过程感觉很疲惫 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93775414031, createdName=ms1011445849213233, createdTime=Wed Jun 13 14:31:34 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=841361, encodeId=f31684136141, content=看中了期刊的一个si，去年9月份投稿，11月中旬收到大修通知，修改1个月后提交，12月底又通知小修，修改10天之后提交。今年2月底通知录用，昨天publish online。<br> 总体感觉期刊还是非常正规的，投稿周期也属于可以接受的范围之内，期刊今年if增长幅度较大，直奔1.5，希望期刊越办越好，早日进入中科院大三区。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eefb5414002, createdName=ms5441261199713928, createdTime=Thu Mar 08 15:08:40 CST 2018, time=2018-03-08, status=1, ipAttribution=)]
    2021-12-28 小动量

    上传文章有什么要求？

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1106563, encodeId=01f511065632a, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106564, encodeId=6907110656465, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859636, encodeId=08ad859636d5, content=14 october 2019 / accepted: 6 april 2020 / online first： 19 april 2020<br> 2019.10.14 投稿<br> 2020.1.16 返修：三个审稿人：意见中肯<br> 2020.2.2 修回<br> 2020.3.26 再次返修：这次是小修，主要修改参考文献格式<br> 2020.3.29 修回<br> 2020.4.6 接受<br> 2020.4.19 线上发表 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Mon Apr 20 12:50:53 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=853997, encodeId=b08c85399ea9, content=去年十一月投稿，三个月后大修，三个审稿人，给的意见大部分都很中肯，修改了七八天提交后三个月小修，修改两三天后提交后一个月后再次小修，修改提交后一个月后接收，整个过程很长。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11cc5414110, createdName=ms8592312893450551, createdTime=Sat Sep 28 08:19:05 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=845478, encodeId=8cb68454e863, content=年前投稿，5月收到大修意见，专家意见提得很专业也很具体，6月修改提交，今天7月中旬收到录用通知。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae65413999, createdName=ms4600315023772712, createdTime=Thu Jul 19 19:21:34 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=843984, encodeId=924d843984ce, content=审稿速度较慢，每次都是顶格给审稿意见。<br> 专家给的意见还是很靠谱，经历了两轮小修才正式录用，过程感觉很疲惫 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93775414031, createdName=ms1011445849213233, createdTime=Wed Jun 13 14:31:34 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=841361, encodeId=f31684136141, content=看中了期刊的一个si，去年9月份投稿，11月中旬收到大修通知，修改1个月后提交，12月底又通知小修，修改10天之后提交。今年2月底通知录用，昨天publish online。<br> 总体感觉期刊还是非常正规的，投稿周期也属于可以接受的范围之内，期刊今年if增长幅度较大，直奔1.5，希望期刊越办越好，早日进入中科院大三区。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eefb5414002, createdName=ms5441261199713928, createdTime=Thu Mar 08 15:08:40 CST 2018, time=2018-03-08, status=1, ipAttribution=)]
    2021-12-27 MS68862005

    如何判断两种药物之间是协同作用还是相加作用？

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1106563, encodeId=01f511065632a, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106564, encodeId=6907110656465, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859636, encodeId=08ad859636d5, content=14 october 2019 / accepted: 6 april 2020 / online first： 19 april 2020<br> 2019.10.14 投稿<br> 2020.1.16 返修：三个审稿人：意见中肯<br> 2020.2.2 修回<br> 2020.3.26 再次返修：这次是小修，主要修改参考文献格式<br> 2020.3.29 修回<br> 2020.4.6 接受<br> 2020.4.19 线上发表 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Mon Apr 20 12:50:53 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=853997, encodeId=b08c85399ea9, content=去年十一月投稿，三个月后大修，三个审稿人，给的意见大部分都很中肯，修改了七八天提交后三个月小修，修改两三天后提交后一个月后再次小修，修改提交后一个月后接收，整个过程很长。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11cc5414110, createdName=ms8592312893450551, createdTime=Sat Sep 28 08:19:05 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=845478, encodeId=8cb68454e863, content=年前投稿，5月收到大修意见，专家意见提得很专业也很具体，6月修改提交，今天7月中旬收到录用通知。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae65413999, createdName=ms4600315023772712, createdTime=Thu Jul 19 19:21:34 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=843984, encodeId=924d843984ce, content=审稿速度较慢，每次都是顶格给审稿意见。<br> 专家给的意见还是很靠谱，经历了两轮小修才正式录用，过程感觉很疲惫 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93775414031, createdName=ms1011445849213233, createdTime=Wed Jun 13 14:31:34 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=841361, encodeId=f31684136141, content=看中了期刊的一个si，去年9月份投稿，11月中旬收到大修通知，修改1个月后提交，12月底又通知小修，修改10天之后提交。今年2月底通知录用，昨天publish online。<br> 总体感觉期刊还是非常正规的，投稿周期也属于可以接受的范围之内，期刊今年if增长幅度较大，直奔1.5，希望期刊越办越好，早日进入中科院大三区。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eefb5414002, createdName=ms5441261199713928, createdTime=Thu Mar 08 15:08:40 CST 2018, time=2018-03-08, status=1, ipAttribution=)]
    2020-04-20 ms8480212230682571

    14 october 2019 / accepted: 6 april 2020 / online first： 19 april 2020
    2019.10.14 投稿
    2020.1.16 返修：三个审稿人：意见中肯
    2020.2.2 修回
    2020.3.26 再次返修：这次是小修，主要修改参考文献格式
    2020.3.29 修回
    2020.4.6 接受
    2020.4.19 线上发表

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1106563, encodeId=01f511065632a, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106564, encodeId=6907110656465, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859636, encodeId=08ad859636d5, content=14 october 2019 / accepted: 6 april 2020 / online first： 19 april 2020<br> 2019.10.14 投稿<br> 2020.1.16 返修：三个审稿人：意见中肯<br> 2020.2.2 修回<br> 2020.3.26 再次返修：这次是小修，主要修改参考文献格式<br> 2020.3.29 修回<br> 2020.4.6 接受<br> 2020.4.19 线上发表 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Mon Apr 20 12:50:53 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=853997, encodeId=b08c85399ea9, content=去年十一月投稿，三个月后大修，三个审稿人，给的意见大部分都很中肯，修改了七八天提交后三个月小修，修改两三天后提交后一个月后再次小修，修改提交后一个月后接收，整个过程很长。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11cc5414110, createdName=ms8592312893450551, createdTime=Sat Sep 28 08:19:05 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=845478, encodeId=8cb68454e863, content=年前投稿，5月收到大修意见，专家意见提得很专业也很具体，6月修改提交，今天7月中旬收到录用通知。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae65413999, createdName=ms4600315023772712, createdTime=Thu Jul 19 19:21:34 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=843984, encodeId=924d843984ce, content=审稿速度较慢，每次都是顶格给审稿意见。<br> 专家给的意见还是很靠谱，经历了两轮小修才正式录用，过程感觉很疲惫 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93775414031, createdName=ms1011445849213233, createdTime=Wed Jun 13 14:31:34 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=841361, encodeId=f31684136141, content=看中了期刊的一个si，去年9月份投稿，11月中旬收到大修通知，修改1个月后提交，12月底又通知小修，修改10天之后提交。今年2月底通知录用，昨天publish online。<br> 总体感觉期刊还是非常正规的，投稿周期也属于可以接受的范围之内，期刊今年if增长幅度较大，直奔1.5，希望期刊越办越好，早日进入中科院大三区。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eefb5414002, createdName=ms5441261199713928, createdTime=Thu Mar 08 15:08:40 CST 2018, time=2018-03-08, status=1, ipAttribution=)]
    2019-09-28 ms8592312893450551

    去年十一月投稿，三个月后大修，三个审稿人，给的意见大部分都很中肯，修改了七八天提交后三个月小修，修改两三天后提交后一个月后再次小修，修改提交后一个月后接收，整个过程很长。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1106563, encodeId=01f511065632a, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106564, encodeId=6907110656465, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859636, encodeId=08ad859636d5, content=14 october 2019 / accepted: 6 april 2020 / online first： 19 april 2020<br> 2019.10.14 投稿<br> 2020.1.16 返修：三个审稿人：意见中肯<br> 2020.2.2 修回<br> 2020.3.26 再次返修：这次是小修，主要修改参考文献格式<br> 2020.3.29 修回<br> 2020.4.6 接受<br> 2020.4.19 线上发表 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Mon Apr 20 12:50:53 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=853997, encodeId=b08c85399ea9, content=去年十一月投稿，三个月后大修，三个审稿人，给的意见大部分都很中肯，修改了七八天提交后三个月小修，修改两三天后提交后一个月后再次小修，修改提交后一个月后接收，整个过程很长。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11cc5414110, createdName=ms8592312893450551, createdTime=Sat Sep 28 08:19:05 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=845478, encodeId=8cb68454e863, content=年前投稿，5月收到大修意见，专家意见提得很专业也很具体，6月修改提交，今天7月中旬收到录用通知。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae65413999, createdName=ms4600315023772712, createdTime=Thu Jul 19 19:21:34 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=843984, encodeId=924d843984ce, content=审稿速度较慢，每次都是顶格给审稿意见。<br> 专家给的意见还是很靠谱，经历了两轮小修才正式录用，过程感觉很疲惫 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93775414031, createdName=ms1011445849213233, createdTime=Wed Jun 13 14:31:34 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=841361, encodeId=f31684136141, content=看中了期刊的一个si，去年9月份投稿，11月中旬收到大修通知，修改1个月后提交，12月底又通知小修，修改10天之后提交。今年2月底通知录用，昨天publish online。<br> 总体感觉期刊还是非常正规的，投稿周期也属于可以接受的范围之内，期刊今年if增长幅度较大，直奔1.5，希望期刊越办越好，早日进入中科院大三区。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eefb5414002, createdName=ms5441261199713928, createdTime=Thu Mar 08 15:08:40 CST 2018, time=2018-03-08, status=1, ipAttribution=)]
    2018-07-19 ms4600315023772712

    年前投稿，5月收到大修意见，专家意见提得很专业也很具体，6月修改提交，今天7月中旬收到录用通知。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1106563, encodeId=01f511065632a, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106564, encodeId=6907110656465, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859636, encodeId=08ad859636d5, content=14 october 2019 / accepted: 6 april 2020 / online first： 19 april 2020<br> 2019.10.14 投稿<br> 2020.1.16 返修：三个审稿人：意见中肯<br> 2020.2.2 修回<br> 2020.3.26 再次返修：这次是小修，主要修改参考文献格式<br> 2020.3.29 修回<br> 2020.4.6 接受<br> 2020.4.19 线上发表 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Mon Apr 20 12:50:53 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=853997, encodeId=b08c85399ea9, content=去年十一月投稿，三个月后大修，三个审稿人，给的意见大部分都很中肯，修改了七八天提交后三个月小修，修改两三天后提交后一个月后再次小修，修改提交后一个月后接收，整个过程很长。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11cc5414110, createdName=ms8592312893450551, createdTime=Sat Sep 28 08:19:05 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=845478, encodeId=8cb68454e863, content=年前投稿，5月收到大修意见，专家意见提得很专业也很具体，6月修改提交，今天7月中旬收到录用通知。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae65413999, createdName=ms4600315023772712, createdTime=Thu Jul 19 19:21:34 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=843984, encodeId=924d843984ce, content=审稿速度较慢，每次都是顶格给审稿意见。<br> 专家给的意见还是很靠谱，经历了两轮小修才正式录用，过程感觉很疲惫 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93775414031, createdName=ms1011445849213233, createdTime=Wed Jun 13 14:31:34 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=841361, encodeId=f31684136141, content=看中了期刊的一个si，去年9月份投稿，11月中旬收到大修通知，修改1个月后提交，12月底又通知小修，修改10天之后提交。今年2月底通知录用，昨天publish online。<br> 总体感觉期刊还是非常正规的，投稿周期也属于可以接受的范围之内，期刊今年if增长幅度较大，直奔1.5，希望期刊越办越好，早日进入中科院大三区。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eefb5414002, createdName=ms5441261199713928, createdTime=Thu Mar 08 15:08:40 CST 2018, time=2018-03-08, status=1, ipAttribution=)]
    2018-06-13 ms1011445849213233

    审稿速度较慢，每次都是顶格给审稿意见。
    专家给的意见还是很靠谱，经历了两轮小修才正式录用，过程感觉很疲惫

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1106563, encodeId=01f511065632a, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106564, encodeId=6907110656465, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=859636, encodeId=08ad859636d5, content=14 october 2019 / accepted: 6 april 2020 / online first： 19 april 2020<br> 2019.10.14 投稿<br> 2020.1.16 返修：三个审稿人：意见中肯<br> 2020.2.2 修回<br> 2020.3.26 再次返修：这次是小修，主要修改参考文献格式<br> 2020.3.29 修回<br> 2020.4.6 接受<br> 2020.4.19 线上发表 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Mon Apr 20 12:50:53 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=853997, encodeId=b08c85399ea9, content=去年十一月投稿，三个月后大修，三个审稿人，给的意见大部分都很中肯，修改了七八天提交后三个月小修，修改两三天后提交后一个月后再次小修，修改提交后一个月后接收，整个过程很长。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11cc5414110, createdName=ms8592312893450551, createdTime=Sat Sep 28 08:19:05 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=845478, encodeId=8cb68454e863, content=年前投稿，5月收到大修意见，专家意见提得很专业也很具体，6月修改提交，今天7月中旬收到录用通知。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae65413999, createdName=ms4600315023772712, createdTime=Thu Jul 19 19:21:34 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=843984, encodeId=924d843984ce, content=审稿速度较慢，每次都是顶格给审稿意见。<br> 专家给的意见还是很靠谱，经历了两轮小修才正式录用，过程感觉很疲惫 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93775414031, createdName=ms1011445849213233, createdTime=Wed Jun 13 14:31:34 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=841361, encodeId=f31684136141, content=看中了期刊的一个si，去年9月份投稿，11月中旬收到大修通知，修改1个月后提交，12月底又通知小修，修改10天之后提交。今年2月底通知录用，昨天publish online。<br> 总体感觉期刊还是非常正规的，投稿周期也属于可以接受的范围之内，期刊今年if增长幅度较大，直奔1.5，希望期刊越办越好，早日进入中科院大三区。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eefb5414002, createdName=ms5441261199713928, createdTime=Thu Mar 08 15:08:40 CST 2018, time=2018-03-08, status=1, ipAttribution=)]
    2018-03-08 ms5441261199713928

    看中了期刊的一个si，去年9月份投稿，11月中旬收到大修通知，修改1个月后提交，12月底又通知小修，修改10天之后提交。今年2月底通知录用，昨天publish online。
    总体感觉期刊还是非常正规的，投稿周期也属于可以接受的范围之内，期刊今年if增长幅度较大，直奔1.5，希望期刊越办越好，早日进入中科院大三区。

    0

共9条页码: 1/1页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分

Baidu
Baidu
map
Baidu
map
Baidu
map